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METHODS
The Swedish Alzheimer Treatment Study (SATS) is a prospective, observational, multicentre study for the longitudinal evaluation of ChEI therapy in clinical practice. This presentation includes all 224 deceased SATS participants diagnosed with mildto-moderate AD (MMSE score 10-26 at the initiation of ChEI treatment, i.e., at the time of diagnosis) who were admitted to NHs during the study period. Sociodemographic characteristics, APOE genotype, dates of NHP and death were recorded. Cognitive abilities, e.g., MMSE scores, were assessed at the start of ChEI therapy (baseline) and semi-annually over 3 years. Chi-square tests (Table 1) were performed to analyse categorical variables. Independent-samples t tests (Table 1) and one-way analysis of variance (ANOVA) with Bonferroni correction (Figures 1-4) were used to compare differences between the means obtained for two and four groups, respectively. 16.6 (14.3-18.9 ) months, p = 0.001. In mild AD, individuals ≤77 years old also exhibited a longer survival time in NHs than those ≥78 years old: 5.1 (4.3-5.9) years vs. 3.9 (3.2-4.5) years, p = 0.025. Moreover, younger participants with mild AD had a longer life-span from AD diagnosis than their older counterparts: 7.0 (6.2-7.8) years vs. 5.2 (4.5-5.9) years, p = 0.001; however, these differences were not detected among patients with moderate AD. No sex differences were observed among the four groups. 
